A proposed overhaul of Medicaid drug pricing under the Trump administration could reshape how prescription costs are managed—but key details remain uncertain. While the plan aims to cut expenses by allowing states to negotiate lower prices for certain medications, it hinges on voluntary participation, leaving many questions about which drugs would be impacted and how widely the changes would apply. Without clear guidelines or mandatory adoption, the effectiveness of the policy depends on state-level decisions, raising concerns about uneven implementation across the country. Critics and advocates alike are watching closely as the framework takes shape.
The Trump administration's efforts to lower drug prices included promised changes to Medicaid. But it's still unclear which drugs will be affected. And each state has to opt in.
